Log in
As a result of our discoveries of a new splice variant (ASIC1b) and a new member (ASIC4) of the ASIC family, and elucidation of their roles in pain caused by tissue acidity, several pharmaceutical companies are now working on ASIC-targeted analgesics and one company has been set up specifically to focus on this work. ASIC-related therapies for a wide variety of conditions are now in clinical trials, with substantial patient involvement. Our work has allowed new therapeutic applications to be conceived for already existing prescribed compounds, and for naturally-occurring compounds, that act on ASICs. Thus, our research on ASICs has had clinical and commercial impact.
Clare Stanford's group has opened up a new line of research for drug treatment of Attention Deficit Hyperactivity Disorder. Based on this work, UCL Business has been awarded an EU patent for the NK1R `knockout' mouse as an investigative tool and pharmaceutical screen. Cerebricon, a subsidiary of Charles River, has taken an exclusive licence to market this mouse and advertise it on their website. Our studies have also enabled us to identify a new genetic locus in which abnormalities are linked to ADHD in humans, and to identify a new drug candidate for treating ADHD.
Research by Dr Andrew Martin at the UCL Research Department of Structural & Molecular Biology has led to a series of antibody-related tools being made available for free use over the Web. One of these, Abysis, has been visited over 360,000 times by over 8,000 users. Abysis has also been released under a commercial license and has been purchased by companies ranging from small biotechs to large pharma for use in their antibody therapeutic development pipelines, allowing them to identify unusual features of their sequences and to improve strategies for humanisation. Martin has also acted as an expert witness for drug companies in patent disputes.
Professor David Feldman's research has influenced thinking about antisemitism, racism and multiculturalism among a range of organisations and policy makers. Since becoming first director of the Pears Institute for the Study of Antisemitism in 2010, he has shaped its development by pursuing a distinctive course of public engagement, with partners such as the All Party Parliamentary Group Against Antisemitism, underpinned by the insights of his research over two decades. As a result, he and the Pears Institute are recognised as significant forces shaping public discourse and policy thinking on issues related to antisemitism.
Research by Marianne Odlyha and her group at the Department of Biological Sciences, Birkbeck, University of London, has led to the development of minimally invasive analytical methods and portable tools (dosimeters) for assessing damage to historical artefacts. These dosimeters are now in use at locations around the world, including the Tate Gallery's store rooms, English Heritage properties (Apsley House) and museums in Ghent, Cracow and Mexico. Methods for assessing damage, and for mitigation of pollutant impact on objects in museum enclosures, have been disseminated to conservation professionals through workshops and training courses held across Europe. The assessment and prevention of damage is vital to conserve the cultural as well as the monetary value of artefacts.
John Martin's painting `Destruction of Pompeii and Herculaneum' was damaged and considered lost until advances in conservation made a restoration feasible. The question remained of how to fill the lost section without generating attentional distraction. Together with TATE Britain, Tim J. Smith used eyetracking to identify restoration procedures that directed gaze towards the remaining content and allowed full comprehension of the painting's subject matter. The restored painting is now on permanent display at TATE. This study is the first to apply eyetracking and vision science to art conservation, and has been received with great interest by the international conservation community.
UCL spin-out company BioVex was launched in 1999 to exploit research undertaken by David Latchman at the UCL Medical Molecular Biology Unit, Department of Biochemistry. (This department is now part of the Department of Structural and Molecular Biology, UCL/Birkbeck and Latchman is now Master of Birkbeck.) Biovex worked to develop inactivated herpes simplex viruses as therapies, and a promising dual-action oncolytic vaccine for solid tumours, OncoVEXGM-CSF, was taken into successful Phase II trials. In 2011 the company was bought out by Amgen for $1 billion — still the largest ever cash sale of a UK biotech — and Amgen has now taken this virus into a Phase III trial with promising initial results.
The CATH classification of protein structure, developed at the Institute of Structural and Molecular Biology, UCL, by Janet Thornton and Christine Orengo, has been used widely across the pharmaceutical industry and academia to guide experiments on proteins. This has led to significant cost and time savings in drug discovery. The UCL-hosted online CATH database receives around 10,000 unique visitors per month, and is a partner in InterPro — the most frequently accessed protein function annotation server available.
Combinatorial Domain Hunting (CDH) technology is a technique for producing fragments of proteins that are soluble and tractable for biophysical analysis. It was developed between 1999 and 2008 at Birkbeck College, in the laboratory of Dr Renos Savva. This technology was patented in 2001 and the biotech company Domainex Ltd was then formed to commercialise it. In 2007, Domainex merged with a UCL spinout company, NCE Discovery Ltd. The company has attracted over £3m in investment and employs about 31 people. In addition to its contract research programme, it has developed an in-house drug discovery programme utilising CDH. Early in 2012 a patent was filed on a series of inhibitors of the protein kinases IKK03b5 and TBK1, which are validated drug targets for cancer and inflammation, and the first of these are expected to begin clinical trials in 2014.
Annette Karmiloff-Smith is a world-leading scientist in the field of cognitive development. This case study describes her ongoing work for Procter & Gamble (P&G) as their scientific consultant for baby development that is based on her research into typical and atypical child development. She designed and wrote booklets, DVDs, and articles for the Pampers.com website on different aspects of child development, sleep, and parent-child interactions. This information has reached millions of parents worldwide. She also checks the scientific correctness of the educational information that P&G communicates on its website, and of statements made by P&G advertising.